Beacon Pointe Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Beacon Pointe Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-39,700	Closed	-$90.5K	–	1333
2024 Q2	$90.5K	Sell	39,700 -4,000	-9%	-$15.3K	﹤0.01%	1230
2024 Q1	$189K	Hold	43,700	–	–	﹤0.01%	1277
2023 Q4	$133K	Buy	43,700 +700	+2%	+$1.31K	﹤0.01%	1257
2023 Q3	$61.9K	Buy	+43,000	New	+$83.2K	﹤0.01%	1303
2022 Q4	–	Sell	-13,200	Closed	-$164K	–	1113
2022 Q3	$164K	Buy	13,200 +1,300	+11%	+$14.9K	﹤0.01%	943
2022 Q2	$58K	Buy	11,900 +400	+3%	+$2.21K	﹤0.01%	1021
2022 Q1	$87K	Buy	+11,500	New	+$109K	﹤0.01%	1163

Beacon Pointe Advisors's GTHX Position: Q3 2024 in Review

Beacon Pointe Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 39,700 shares — an estimated $90.5K sold.

Beacon Pointe Advisors first reported a position in GTHX in Q1 2022 and held it in 7 quarters. The position peaked at $189K in Q1 2024. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

Beacon Pointe Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Beacon Pointe Advisors sold 39,700 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $90.5K.
Beacon Pointe Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Beacon Pointe Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $189K in Q1 2024.
0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Beacon Pointe Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.